Thomas Brennan Email & Phone Number

2024 - PresentSVP of Nonclinical Operations at Mahzi Therapeutics Inc., overseeing strategy to plan and generate preclinical efficacy, safety, biomarker, and bioanalytics data packages for regulatory filings. Our focus is on rare genetic neurodevelopmental disorders, which have limited treatment options.2019 - 2023Cofounder of Walking Fish Therapeutics Inc. (WFT). Managed preclinical development for 4.5 years, advancing B cell engineering, culture conditions, and in vivo models for B cell therapies. Led preclinical toxicology and murine modeling for the lead indication; Fabry’s disease.2005 - 2019Head of Pharmacology (2005) and VP of Pharmacology (2016) at FivePrime Therapeutics Inc. Directed preclinical pharmacology for numerous programs, including Bemarituzimab (approved for gastric cancer), and 4 other IND's including FPT155 (CD80-Fc). Managed pharmacology leading to 5 INDs and various programs, led large teams in diverse disease areas for target discovery using novel in vivo approaches with large pharma partners including Pfizer and UCB, and established a bioanalytics department while developing a comprehensive translational biology database.2003 - 2005CEO and cofounder of a biotech company specializing in murine models for CNS disorder target identification.1997 - 2003Senior Scientist at Deltagen Inc., co-managing transgenic and phenotyping operations of 1500 mouse knockouts.Education and Postdoctoral PositionsPhD in Biomedicine (1990) from the University of Texas Health Science Center in Houston, focusing on myogenin and muscle cell fate. Postdoctoral research at Genentech and UCSF.